Zscaler to Host Fourth Quarter Fiscal Year 2025 Earnings Conference Call

(NASDAQ:ZS), SAN JOSE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, will release fourth quarter fiscal year 2025 earnings after the market closes on Tuesday, September 2, 2025. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) […]

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

(HKSE:6855),(NasdaqGM:AAPG), ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company“), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at

Pet Innovation Awards Honors Full Moon(R) Pure Protein(TM) as “Air-Dried Dog Food Product of the Year”

Pet Innovation Awards Honors Full Moon(R) Pure Protein(TM) as “Air-Dried Dog Food Product of the Year” Annual Awards Program Recognizes New Dog Food Meals for Exemplifying Excellence and Innovation GlobeNewswire August 07, 2025 SANTA MONICA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — The 2025 Pet Innovation Awards announced that it has selected the new Pure

Stryker declares an $0.84 per share quarterly dividend

(NYSE:SYK), Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from

Sensoril(R) From Kerry Group Receives Award For “Dog Stress Relief Product of the Year” In 2025 Pet Innovation Awards

Sensoril(R) From Kerry Group Receives Award For “Dog Stress Relief Product of the Year” In 2025 Pet Innovation Awards Annual Awards Program Recognizes Companies, Services And Products Within The Rapidly Expanding Pet Industry That Exemplify Excellence & Innovation GlobeNewswire August 07, 2025 LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) — The 2025 Pet Innovation Awards

The Provident Bank Foundation Announces 2025 Empowerment Grant Recipients

(NYSE:PFS), WOODBRIDGE, NJ, Aug. 07, 2025 (GLOBE NEWSWIRE) — The Provident Bank Foundation (PBF) is proud to announce the recipients of its inaugural Empowerment Grant cycle. Amid the current challenging landscape for the nonprofit sector, PBF's Board of Directors has approved 41 multi-year grants totaling $515,000 in funding annually to support the missions of nonprofit

Tailr Receives 2025 Pet Innovation Award For “ID & Tag Product of the Year”

Tailr Receives 2025 Pet Innovation Award For “ID & Tag Product of the Year” Annual Awards Program Recognizes Companies, Services And Products Within The Rapidly Expanding Pet Industry That Exemplify Excellence & Innovation GlobeNewswire August 07, 2025 LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) — The 2025 Pet Innovation Awards today announced that Tailr, the

Anteriad Celebrates 25 Years of Growth for B2B Marketers

Rye Brook, New York, Aug. 07, 2025 (GLOBE NEWSWIRE) — Anteriad, a global leader in data- and AI-driven, tech enabled B2B marketing solutions is celebrating 25 years since the company was originally founded. Anteriad has continuously evolved to deliver market-leading solutions for B2B marketers and an expanding roster of enterprise customers around the globe. Today,

Now Fresh Good Gravy(TM) from Petcurean Named “Dog Bone Broth Product of the Year” by Pet Innovation

Now Fresh Good Gravy(TM) from Petcurean Named “Dog Bone Broth Product of the Year” by Pet Innovation Annual Awards Program Recognizes Companies, Services And Products Within The Rapidly Expanding Pet Industry That Exemplify Excellence & Innovation GlobeNewswire August 07, 2025 LOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) — The 2025 Pet Innovation Awards today announced

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

(NASDAQ:MBX), Topline results for the Phase 2 Avail(TM) trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 2025 MBX 4291 Phase 1 trial initiation in obesity anticipated in Q3 2025 $224.9 million in cash, cash equivalents and marketable securities

Scroll to Top